Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non–small-cell lung cancer (RADIANT): A randomized, double-blind, phase III trial

K Kelly, NK Altorki, WEE Eberhardt… - Journal of Clinical …, 2015 - escholarship.org
PurposeEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have proven
efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib …
被引用次数：488 相关文章

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

K Kelly, NK Altorki, WEE Eberhardt… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

K Kelly, NK Altorki, WEE Eberhardt, MER O'Brien… - 2015 - scholarworks.bwise.kr
Purpose Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have proven
efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

K Kelly, NK Altorki, WEE Eberhardt… - Journal of clinical …, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have proven
efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib …
[PDF] academia.edu

[PDF][PDF] Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung

K Kelly, NK Altorki, WEE Eberhardt - Journal of clinical oncology …, 2015 - academia.edu
UC Davis Page 1 UC Davis UC Davis Previously Published Works Title Adjuvant Erlotinib
Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A …

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

K Kelly, NK Altorki, WEE Eberhardt… - JOURNAL OF …, 2015 - research.unipg.it
Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have proven
efficacy in advanced nonsmall-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Adjuvant erlotinib versus placebo in patients with stage IB-IIIA nonsmall-cell lung cancer (RADIANT): A randomized, double-blind, Phase III trial

K Kelly, NK Altorki, WEE Eberhardt… - Journal of Clinical …, 2015 - elibrary.ru
Purpose Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have proven
efficacy in advanced nonsmall-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

K Kelly, NK Altorki, WE Eberhardt… - Journal of Clinical …, 2015 - europepmc.org
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer
(RADIANT): A Randomized, Double-Blind, Phase III Trial. - Abstract - Europe PMC Sign in …

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

K Kelly, NK Altorki, WEE Eberhardt… - Journal of Clinical …, 2015 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Epidermal growth factor receptor
(EGFR)–tyrosine kinase inhibitors have proven efficacy in advanced non–small-cell lung …